Syndax Pharmaceuticals, Inc. (SNDX) Earnings Call Transcripts
Syndax Pharmaceuticals, Inc.'s Latest Earnings Call - June 10, 2026
During the 2026 Annual Meeting of Stockholders for Syndax Pharmaceuticals, no financial results or guidance updates were disclosed, leading to a lack of new information that could impact the stock. The meeting focused on the election of directors and approval of various compensation and incentive plans. As there were no earnings or revenue figures shared, investors may want to remain cautious until further details are provided in future communications.
Reported metrics
| Metric | Value |
|---|---|
| Shareholder Participation | 75% (positive) |
| Executive Compensation Approval | 94% (positive) |
| Auditor Approval | 99% (positive) |
| Equity Incentive Plan Approval | 56% (neutral) |
| Employee Stock Purchase Plan Approval | 99% (positive) |
What management said
I have a complete list of the stockholders of record of the company's common stock on April 21, 2026, the record date for this meeting. I also have an affidavit certifying that on April 30, 2026, a notice of Annual Meeting of Stockholders of the company was deposited in the United States mail to all stockholders of record.
At this time, I would like to introduce Sue Nelson of Computershare. I'm appointing Ms. Nelson to act as the Inspector of Election at this meeting. Ms. Nelson has taken and subscribed to customary oath of office to execute her duties with strict de-partiality. We will file this oath with the records of the meeting. Her function is to decide upon the qualification of voters, accept their votes and when balloting on al...
What analysts pressed on
Analysts may be concerned about the lack of financial updates or guidance during the meeting, as no earnings or revenue figures were disclosed. This absence of information could lead to uncertainty regarding the company's performance and future outlook.
Main topics on the call
- Director Elections — The meeting successfully elected Pierre Legault and Michael Metzger as Class I Directors, with each receiving majority support from shareholders. This indicates strong governance and continuity in leadership.
- Compensation Approval — The advisory vote on executive compensation received over 94% approval, reflecting shareholder confidence in the management team's performance and compensation structure.
- Auditor Ratification — Deloitte & Touche was ratified as independent auditors for the fiscal year ending 2026 with over 99% voting in favor, suggesting strong trust in the auditing process.
- Equity Incentive Plan Approval — The approval of the 2026 Equity Incentive Plan was carried with over 56% support, indicating a commitment to incentivizing performance among employees.
Read the full Syndax Pharmaceuticals, Inc. transcript (June 10, 2026) → Summary generated from the call transcript; every figure above is stated by management on the record.
About Syndax Pharmaceuticals, Inc.
Syndax Pharmaceuticals, Inc. (SNDX) is a publicly listed company in the Biotechnology industry, within the Health Care sector. It trades on NasdaqGS and is based in US. EarningsCalls.dev maintains a free, full-text archive of its earnings call transcripts — 75 calls on record spanning March 3, 2020 to August 4, 2026. Every transcript is split into speaker-by-speaker segments with headline metrics, free to read or available through our REST API.
Earnings Call History
EarningsCalls.dev has 75 Syndax Pharmaceuticals, Inc. earnings call transcripts on record, spanning March 3, 2020 to August 4, 2026. Based on this history, Syndax Pharmaceuticals, Inc. reports quarterly. The most recent call on file is dated August 4, 2026. The full list is below — each row opens the complete, free-to-read transcript.
- Ticker
- SNDX
- Exchange
- NasdaqGS
- Country
- US
- Sector
- Health Care
- Industry
- Biotechnology
- Calls on record
- 75
- First call
- March 3, 2020
- Most recent
- August 4, 2026
- Reporting cadence
- quarterly